Auriga

Auriga raises its rating on Salix Pharmaceuticals (NASDAQ: SLXP) to Buy and raises its price target to $54 on more robust growth of Xifaxan. Auriga notes, "Xifaxan growth picked up significantly during the second half of 2011 primarily due to seasonality. Management's 2012 guidance appears...

Auriga raises its price target on Buy-rated JAZZ Pharmaceuticals (NASDAQ: JAZZ) to $57 from $55 as the company posted another consensus-beating quarter. Auriga says, "We remain impressed by Jazz's execution, as the company had another quarter of record revenue and EPS. The company also closed the...

Auriga raises its price target on Buy-rated Universal Health Services (NYSE: UHS) to $51 from $45 on in-line Q4 and likely conservative 2012 guidance. Auriga notes, "UHS issued EPS guidance range to $4.33-$4.48 (v. consensus $4.42) on revenue increase of +5% to $7.24B. Note that revenue guidance...

Auriga maintains its Buy rating and $9 target price on eResearch (NASDAQ: ERT) as it believes the stock remains undervalued following solid Q4 and outlook. Auriga says, "We are reiterating our BUY rating on eResearch Technology (ERT) on the heels of a strong Q4 in which bookings, revenue and EPS...

Auriga raises its price target on Buy-rated EXACT Sciences (NASDAQ: EXAS) to $13 from $10 on a potential clinical update in 2Q. Auriga says, "Exact Sciences reported 4Q11 results of $1.0MM/$(0.18). Given EXAS is a development stage company, earnings are not as important as clinical milestones...

According to Auriga, Herbalife (NYSE: HLF) price target is raised to $66. Auriga said that Herbalife reported strong 4Q and FY11 results, exceeding its expectations as well as consensus estimates. “With the higher guidance, we are raising our FY12 estimate to $3.61 from $3.49 and to $4.10 from $3....

According to Auriga, the Medicines Company (NASDAQ: MDCO) price target is raised to $25. Auriga said that MDCO had a strong quarter due to high demand of Angiomax, with results handily beating consensus on both revenue and EPS. “We reiterate BUY and raise price target to $25.00.” The Medicines...

According to a research report published earlier today, Auriga has lowered Yingli Green Energy's (NYSE: YGE) PT from $5.00 to $3.50. Auriga explained the reason for the change: “Yingli Green is a negative surprise on shipments, gross margins, and the magnitude of its inventory/asset write-offs....

In a recent research report, Auriga has updated Trina Solar's (NYSE: TSL) 2012 estimates from $0.29 to $0.25, and revenue from $1,530M to $1,601M. In the report, Auriga noted, “At $10.33 TSL compares to C2012 EPS estimate of ($0.25) and ~23.0x our C2013 EPS of $0.45. To value solar PV stocks we...

According to a research report released earlier today, Auriga has increased Canadian Solar Inc.'s (NASDAQ: CSIQ) PT from $3.00 to $4.00. In the report, Auriga commented, “Canadian Solar definitely is a positive surprise on shipments. Further, the company is a rare case in the solar PV industry in...

According to a research report released earlier today, Auriga has increased Suntech Power Holdings Co.'s (NYSE: STP) PT from $3.00 to $3.50. In the report, Auriga explained, “While Suntech Power's shipments improved its working capital position and lowered the possibility of inventory write-offs,...

According to a research report published earlier today, Auriga has maintained its Hold rating on Community Health Systems (NYSE: CYH) due to government investigation with an unclear timeline/settlement. In the report, Auriga said, “CYH reported non-GAAP EPS of $0.90 (based on our calculation),...

In a research report published earlier today, Auriga increased its IQ EPS estimate on HEICO Corporation (NYSE: HEI) from $0.45 to $0.47. Auriga said, “Our optimism primarily stems from higher revenue assumptions, as we expect the company's commercial business performed well during the period. We...

In a research report published today by Auriga, Chiquita Brands International (NYSE: CQB) reported lower revenue and improved EPS for its 4QFY11. In the report, Auriga said, “Despite a weaker pricing to start the year, recent improvements in market conditions and the implementation of a North...

Auriga maintains its Buy rating and $12 target price on Chiquita Brands (NYSE: CQB) ahead of Q4 release, which is expected to feature improved results on better weather in Latin America compared to last year. Auriga says, "We are expecting Chiquita to report 4Q revenue of $765.3 million,...